

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CK Life Sciences Int'l. (Holdings) Inc.

長江生命科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0775)

BUSINESS UPDATE ON DOGWOOD THERAPEUTICS, INC.

CK Life Sciences Int'l. (Holdings) Inc. (the “Company”) wishes to provide an update regarding its investment in Dogwood Therapeutics, Inc. (“Dogwood”). Dogwood is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathic disorders which is incorporated in Delaware and listed on the Nasdaq Capital Market under the ticker symbol DWTX. The Company currently holds an approximate 83% indirect shareholding interest in Dogwood.

On December 22, 2025, after Hong Kong trading hours, Dogwood announced positive results from an interim analysis of 97 patients who had completed treatment in the ongoing Halneuron® Phase 2b chemotherapy-induced neuropathic pain (“CINP”) study. The independent statistical review committee reviewed unblinded patient treatment data from the Phase 2b trial and concluded that Halneuron® treated patients are demonstrating separation from placebo treated patients in terms of pain improvement over the four-week study.

According to Dogwood, this preliminary evidence of a Halneuron® treatment effect is noteworthy as patients in the interim analysis population present an average duration of CINP of 5 years and 67% of patients that met entry criteria were also being treated with stable doses of other chronic pain medicines, including pregabalin, gabapentin, duloxetine, and opioids. In addition, the overall study dropout rate of approximately 4.4% is far below rates observed with other FDA approved chronic pain medicines. While still blinded, Dogwood believes this finding reaffirms the encouraging safety and tolerability profile of Halneuron® observed in previous clinical trials.

Based on the current Phase 2b trial enrollment pace and the interim assessment results, Dogwood continues to expect to have top-line results available during Q3 2026. The current study is projected to provide statistical power of approximately 80% to 85% to detect a Halneuron® treatment difference.

It should be noted that Halneuron® is still at the Phase 2b clinical trial stage for CINP and the data is subject to further review by the relevant regulatory authorities. There is accordingly no assurance of the outcome. Shareholders of the Company and potential investors are therefore advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
CK Life Sciences Int'l. (Holdings) Inc.
Eirene Yeung
Company Secretary

Hong Kong, 23 December 2025

As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel, Mr. Lance Richard Lee Yuen and Dr. Toh Kean Meng, Melvin; and the Non-executive Directors are Mr. Peter Peace Tulloch, Mrs. Kwok Eva Lee (Independent Non-executive Director), Mr. Kwan Kai Cheong (Independent Non-executive Director), Mr. Paul Joseph Tighe (Independent Non-executive Director) and Mr. Donald Jeffrey Roberts (Independent Non-executive Director).